Brian A Keller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9504295/publications.pdf

Version: 2024-02-01

1307594 1474206 10 194 7 9 citations g-index h-index papers 10 10 10 413 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nature Communications, 2022, 13, 1898.	12.8	16
2	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	2.5	2
3	Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. Methods in Molecular Biology, 2020, 2058, 271-284.	0.9	O
4	Performance report for a 10-year-old MD/PhD Program: A survey of trainees at the University of Ottawa. Clinical and Investigative Medicine, 2020, 43, E1-13.	0.6	2
5	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. Molecular Therapy - Oncolytics, 2019, 14, 179-187.	4.4	16
6	Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy, 2019, 27, 1139-1152.	8.2	41
7	Dimethyl fumarate potentiates oncolytic virotherapy through NF- $\hat{\mathbb{I}}^2$ B inhibition. Science Translational Medicine, 2018, 10, .	12.4	44
8	Oncolytic Viruses: The Best is Yet to Come. Current Cancer Drug Targets, 2018, 18, 109-123.	1.6	19
9	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics, 2016, 3, 16027.	4.4	11
10	Oncolytic virusesâ€"immunotherapeutics on the rise. Journal of Molecular Medicine, 2016, 94, 979-991.	3.9	43